Is IMCR or SRRK more profitable?

Scholar Rock has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Immunocore -4.20% -4.54% -1.66% Scholar Rock N/A -160.19% -87.18%

Does the media favor IMCR or SRRK?

In the previous week, Scholar Rock had 4 more articles in the media than Immunocore. MarketBeat recorded 10 mentions for Scholar Rock and 6 mentions for Immunocore. Scholar Rock's average media sentiment score of 1.49 beat Immunocore's score of 1.00 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, CGON or IMCR?

Immunocore has higher revenue and earnings than CG Oncology. Immunocore is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $6.23M 1,058.04 -$160.99M -$2.69 N/A Immunocore $430.78M 4.38 -$35.51M -$0.37 N/A

Does the media refer more to CGON or IMCR?

In the previous week, CG Oncology and CG Oncology both had 6 articles in the media. CG Oncology's average media sentiment score of 1.55 beat Immunocore's score of 1.00 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Immunocore 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ORKA or IMCR?

In the previous week, Oruka Therapeutics had 6 more articles in the media than Immunocore. MarketBeat recorded 12 mentions for Oruka Therapeutics and 6 mentions for Immunocore. Oruka Therapeutics' average media sentiment score of 1.45 beat Immunocore's score of 1.00 indicating that Oruka Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IMCR or MIRM?

In the previous week, Mirum Pharmaceuticals had 14 more articles in the media than Immunocore. MarketBeat recorded 20 mentions for Mirum Pharmaceuticals and 6 mentions for Immunocore. Mirum Pharmaceuticals' average media sentiment score of 1.27 beat Immunocore's score of 1.00 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 13 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IMCR or COGT?

In the previous week, Cogent Biosciences had 6 more articles in the media than Immunocore. MarketBeat recorded 12 mentions for Cogent Biosciences and 6 mentions for Immunocore. Cogent Biosciences' average media sentiment score of 1.59 beat Immunocore's score of 1.00 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 11 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Immunocore (IMCR) Competitors

$36.62 -0.13 (-0.35%)

As of 08/28/2026 04:00 PM Eastern

Compare

IMCR vs. SRRK, CGON, ORKA, MIRM, and COGT

Should you buy Immunocore stock or one of its competitors? Immunocore's main competitors and comparable companies include Scholar Rock (SRRK), CG Oncology (CGON), Oruka Therapeutics (ORKA), Mirum Pharmaceuticals (MIRM), and Cogent Biosciences (COGT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immunocore compare to Scholar Rock?

Immunocore (NASDAQ:IMCR) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Immunocore has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

84.5% of Immunocore shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 10.1% of Immunocore shares are owned by insiders. Comparatively, 10.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Scholar Rock had 4 more articles in the media than Immunocore. MarketBeat recorded 10 mentions for Scholar Rock and 6 mentions for Immunocore. Scholar Rock's average media sentiment score of 1.49 beat Immunocore's score of 1.00 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-4.20%	-4.54%	-1.66%
Scholar Rock	N/A	-160.19%	-87.18%

Immunocore has higher revenue and earnings than Scholar Rock. Immunocore is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$430.78M	4.38	-$35.51M	-$0.37	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

Immunocore currently has a consensus target price of $56.38, indicating a potential upside of 53.95%. Scholar Rock has a consensus target price of $58.77, indicating a potential upside of 1.68%. Given Immunocore's higher possible upside, equities research analysts clearly believe Immunocore is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.69
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	3.13

Summary

Scholar Rock beats Immunocore on 9 of the 16 factors compared between the two stocks.

How does Immunocore compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Immunocore (NASDAQ:IMCR) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

Immunocore has a net margin of -4.20% compared to CG Oncology's net margin of -3,602.68%. Immunocore's return on equity of -4.54% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Immunocore	-4.20%	-4.54%	-1.66%

CG Oncology currently has a consensus target price of $83.18, suggesting a potential upside of 11.89%. Immunocore has a consensus target price of $56.38, suggesting a potential upside of 53.95%. Given Immunocore's higher possible upside, analysts plainly believe Immunocore is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.69

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by insiders. Comparatively, 10.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Immunocore has higher revenue and earnings than CG Oncology. Immunocore is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$6.23M	1,058.04	-$160.99M	-$2.69	N/A
Immunocore	$430.78M	4.38	-$35.51M	-$0.37	N/A

CG Oncology has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

In the previous week, CG Oncology and CG Oncology both had 6 articles in the media. CG Oncology's average media sentiment score of 1.55 beat Immunocore's score of 1.00 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Immunocore	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Immunocore beats CG Oncology on 11 of the 16 factors compared between the two stocks.

How does Immunocore compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Immunocore (NASDAQ:IMCR) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Oruka Therapeutics has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-21.65%	-20.88%
Immunocore	-4.20%	-4.54%	-1.66%

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by company insiders. Comparatively, 10.1% of Immunocore shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Oruka Therapeutics has a beta of -0.34, meaning that its stock price is 134% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

Oruka Therapeutics currently has a consensus price target of $134.30, suggesting a potential upside of 47.36%. Immunocore has a consensus price target of $56.38, suggesting a potential upside of 53.95%. Given Immunocore's higher possible upside, analysts plainly believe Immunocore is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.69

Immunocore has higher revenue and earnings than Oruka Therapeutics. Immunocore is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
Immunocore	$430.78M	4.38	-$35.51M	-$0.37	N/A

In the previous week, Oruka Therapeutics had 6 more articles in the media than Immunocore. MarketBeat recorded 12 mentions for Oruka Therapeutics and 6 mentions for Immunocore. Oruka Therapeutics' average media sentiment score of 1.45 beat Immunocore's score of 1.00 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunocore	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Immunocore beats Oruka Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Immunocore compare to Mirum Pharmaceuticals?

Immunocore (NASDAQ:IMCR) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Immunocore has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

84.5% of Immunocore shares are owned by institutional investors. 10.1% of Immunocore shares are owned by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Immunocore currently has a consensus price target of $56.38, indicating a potential upside of 53.95%. Mirum Pharmaceuticals has a consensus price target of $137.31, indicating a potential upside of 40.89%. Given Immunocore's higher possible upside, equities analysts clearly believe Immunocore is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.69
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Mirum Pharmaceuticals had 14 more articles in the media than Immunocore. MarketBeat recorded 20 mentions for Mirum Pharmaceuticals and 6 mentions for Immunocore. Mirum Pharmaceuticals' average media sentiment score of 1.27 beat Immunocore's score of 1.00 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	13 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$430.78M	4.38	-$35.51M	-$0.37	N/A
Mirum Pharmaceuticals	$618.07M	10.24	-$23.36M	-$14.55	N/A

Immunocore has a net margin of -4.20% compared to Mirum Pharmaceuticals' net margin of -139.18%. Immunocore's return on equity of -4.54% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-4.20%	-4.54%	-1.66%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Summary

Immunocore beats Mirum Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Immunocore compare to Cogent Biosciences?

Immunocore (NASDAQ:IMCR) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Immunocore currently has a consensus target price of $56.38, suggesting a potential upside of 53.95%. Cogent Biosciences has a consensus target price of $49.40, suggesting a potential upside of 42.49%. Given Immunocore's higher probable upside, analysts clearly believe Immunocore is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.69
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

84.5% of Immunocore shares are owned by institutional investors. 10.1% of Immunocore shares are owned by company insiders. Comparatively, 6.6% of Cogent Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Immunocore has higher revenue and earnings than Cogent Biosciences. Immunocore is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$430.78M	4.38	-$35.51M	-$0.37	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A

Immunocore has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

In the previous week, Cogent Biosciences had 6 more articles in the media than Immunocore. MarketBeat recorded 12 mentions for Cogent Biosciences and 6 mentions for Immunocore. Cogent Biosciences' average media sentiment score of 1.59 beat Immunocore's score of 1.00 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	11 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cogent Biosciences has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-4.20%	-4.54%	-1.66%
Cogent Biosciences	N/A	-84.47%	-47.72%

Summary

Immunocore beats Cogent Biosciences on 9 of the 15 factors compared between the two stocks.

Get Immunocore News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMCR vs. The Competition

Export

Metric	Immunocore	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.89B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-98.97	11.62	273.16	25.45
Price / Sales	4.38	1,295.87	605.06	76.64
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	4.49	16.53	12.98	6.14
Net Income	-$35.51M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-0.70%	-0.31%	0.13%	-0.80%
1 Month Performance	8.12%	9.80%	7.08%	4.13%
1 Year Performance	13.66%	55.66%	24.67%	15.17%

Immunocore Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMCR Immunocore	3.6573 of 5 stars	$36.62 -0.4%	$56.38 +53.9%	+13.7%	$1.89B	$430.78M	N/A	320	Positive News
SRRK Scholar Rock	1.7992 of 5 stars	$58.58 +0.7%	$58.77 +0.3%	+77.0%	$7.15B	N/A	N/A	140
CGON CG Oncology	3.242 of 5 stars	$78.76 +0.7%	$83.18 +5.6%	+177.2%	$7.00B	$4.04M	N/A	61
ORKA Oruka Therapeutics	2.8888 of 5 stars	$103.38 +0.9%	$134.30 +29.9%	+515.8%	$6.85B	N/A	N/A	N/A	News Coverage Positive News
MIRM Mirum Pharmaceuticals	3.7178 of 5 stars	$98.93 +2.3%	$137.33 +38.8%	+31.9%	$6.42B	$521.31M	N/A	140	News Coverage Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMCR) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunocore (IMCR) Competitors

IMCR vs. SRRK, CGON, ORKA, MIRM, and COGT

How does Immunocore compare to Scholar Rock?

Summary

How does Immunocore compare to CG Oncology?

Summary

How does Immunocore compare to Oruka Therapeutics?

Summary

How does Immunocore compare to Mirum Pharmaceuticals?

Summary

How does Immunocore compare to Cogent Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR vs. The Competition

Immunocore Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunocore (IMCR) Competitors

IMCR vs. SRRK, CGON, ORKA, MIRM, and COGT

How does Immunocore compare to Scholar Rock?

Which has more risk & volatility, IMCR or SRRK?

Do institutionals & insiders believe in IMCR or SRRK?

Does the media favor IMCR or SRRK?

Is IMCR or SRRK more profitable?

Which has better valuation and earnings, IMCR or SRRK?

Do analysts rate IMCR or SRRK?

Summary

How does Immunocore compare to CG Oncology?

Is CGON or IMCR more profitable?

Do analysts prefer CGON or IMCR?

Do institutionals and insiders hold more shares of CGON or IMCR?

Which has preferable valuation & earnings, CGON or IMCR?

Which has more risk & volatility, CGON or IMCR?

Does the media refer more to CGON or IMCR?

Summary

How does Immunocore compare to Oruka Therapeutics?

Is ORKA or IMCR more profitable?

Do institutionals & insiders hold more shares of ORKA or IMCR?

Which has more volatility and risk, ORKA or IMCR?

Do analysts rate ORKA or IMCR?

Which has preferable earnings & valuation, ORKA or IMCR?

Does the media favor ORKA or IMCR?

Summary

How does Immunocore compare to Mirum Pharmaceuticals?

Which has more volatility and risk, IMCR or MIRM?

Do insiders and institutionals believe in IMCR or MIRM?

Do analysts prefer IMCR or MIRM?

Does the media favor IMCR or MIRM?

Which has stronger valuation & earnings, IMCR or MIRM?

Is IMCR or MIRM more profitable?

Summary

How does Immunocore compare to Cogent Biosciences?

Do analysts prefer IMCR or COGT?

Do insiders & institutionals hold more shares of IMCR or COGT?

Which has stronger earnings and valuation, IMCR or COGT?

Which has more volatility & risk, IMCR or COGT?

Does the media prefer IMCR or COGT?

Is IMCR or COGT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR vs. The Competition

Immunocore Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools